A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate
Phase of Trial: Phase II
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Evobrutinib (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors EMD Serono Research & Development Institute
- 13 Sep 2017 Planned End Date changed from 22 Apr 2019 to 19 Apr 2021.
- 13 Sep 2017 Planned primary completion date changed from 31 Dec 2018 to 24 Mar 2019.
- 13 Sep 2017 Status changed from not yet recruiting to recruiting.